サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1434648

アセタゾラミド市場：剤形、疾患、流通チャネル別-世界予測2024-2030年

Acetazolamide Market by Dosage Form (Capsules, Injection, Tablets), Disease (Altitude Sickness, Epilepsy, Glaucoma), Distribution Channel - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 198 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
アセタゾラミド市場：剤形、疾患、流通チャネル別-世界予測2024-2030年
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 198 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アセタゾラミド市場規模は、2023年に2億8,155万米ドルと推定され、2024年には2億9,950万米ドルに達し、CAGR 6.47%で2030年には4億3,671万米ドルに達すると予測されます。

アセタゾラミドの世界市場

主な市場の統計
基準年[2023］ 2億8,155万米ドル
予測年[2024] 2億9,950万米ドル
予測年 [2030] 4億3,671万米ドル
CAGR（%） 6.47%
アセタゾラミド Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはアセタゾラミド市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、アセタゾラミド市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-アセタゾラミド市場の市場規模および予測は？

2-アセタゾラミド市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-アセタゾラミド市場における技術動向と規制の枠組みは？

4-アセタゾラミド市場における主要ベンダーの市場シェアは？

5-アセタゾラミド市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 国民の間で緑内障や高血圧などの関連危険因子の発生率が増加
      • 緑内障に対する意識を高めるための政府および製薬団体の取り組みの拡大
      • いくつかの治療法におけるアセタゾラミドの適用
    • 抑制要因
      • 製造過程における特定の不具合に関する懸念
      • アセタゾラミドのジェネリック医薬品としての利用可能性を拡大
    • 機会
      • さまざまなタイプのアセタゾラミドの作成におけるイノベーションの高まり
      • アセタゾラミドのジェネリック医薬品としての利用可能性を拡大
    • 課題
      • アセタゾラミドに代わるかなりの代替手段が市場で入手可能
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 アセタゾラミド市場剤形別

  • カプセル
  • 注射
  • タブレット

第7章 アセタゾラミド市場：疾患別

  • 高山病
  • てんかん
  • 緑内障
  • 心不全
  • 特発性頭蓋内圧亢進症
  • 周期的な麻痺

第8章 アセタゾラミド市場：流通チャネル別

  • 病院
  • オンラインドラッグストア
  • 小売ドラッグストア

第9章 南北アメリカのアセタゾラミド市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域のアセタゾラミド市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのアセタゾラミド市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Aquatic Group
    • Avanscure Lifesciences Pvt Ltd.
    • CTX Lifesciences Pvt Ltd
    • Emcure Pharmaceuticals Limited
    • Heritage Pharmaceuticals Inc
    • Lannett Co Inc.
    • Lannett Company, Inc.
    • LGM Pharma, LLC
    • Manus Aktteva Biopharma LLP
    • Mylan N.V.
    • Nakoda Chemicals Ltd.
    • Ningbo Hi-tech Biochemicals Co Ltd
    • Nostrum Laboratories Inc.
    • Novast Laboratories Ltd.
    • Polpharma SA
    • Shandong Octagon Chemicals Limited
    • Strides Pharma Science Limited
    • Strides Shasun Limited
    • Sun Pharmaceutical Industries
    • Taro Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd
    • X-Gen Pharmaceuticals, Inc.
    • Zydus Pharmaceuticals（USA）Inc.
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ACETAZOLAMIDE MARKET RESEARCH PROCESS
  • FIGURE 2. ACETAZOLAMIDE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ACETAZOLAMIDE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ACETAZOLAMIDE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ACETAZOLAMIDE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ACETAZOLAMIDE MARKET DYNAMICS
  • FIGURE 7. ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 8. ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 10. ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ACETAZOLAMIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ACETAZOLAMIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ACETAZOLAMIDE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ACETAZOLAMIDE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ACETAZOLAMIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ACETAZOLAMIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ACETAZOLAMIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACETAZOLAMIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ACETAZOLAMIDE MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ACETAZOLAMIDE MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ACETAZOLAMIDE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ACETAZOLAMIDE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACETAZOLAMIDE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 6. ACETAZOLAMIDE MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ACETAZOLAMIDE MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ACETAZOLAMIDE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 10. ACETAZOLAMIDE MARKET SIZE, BY ALTITUDE SICKNESS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ACETAZOLAMIDE MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ACETAZOLAMIDE MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ACETAZOLAMIDE MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ACETAZOLAMIDE MARKET SIZE, BY IDIOPATHIC INTRACRANIAL HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ACETAZOLAMIDE MARKET SIZE, BY PERIODIC PARALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. ACETAZOLAMIDE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ACETAZOLAMIDE MARKET SIZE, BY ONLINE DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ACETAZOLAMIDE MARKET SIZE, BY RETAIL DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ACETAZOLAMIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ACETAZOLAMIDE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ACETAZOLAMIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ACETAZOLAMIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ACETAZOLAMIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ACETAZOLAMIDE MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ACETAZOLAMIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. ACETAZOLAMIDE MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 148. ACETAZOLAMIDE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. ACETAZOLAMIDE MARKET LICENSE & PRICING
目次
Product Code: MRR-436901065EB0

[198 Pages Report] The Acetazolamide Market size was estimated at USD 281.55 million in 2023 and expected to reach USD 299.50 million in 2024, at a CAGR 6.47% to reach USD 436.71 million by 2030.

Global Acetazolamide Market

KEY MARKET STATISTICS
Base Year [2023] USD 281.55 million
Estimated Year [2024] USD 299.50 million
Forecast Year [2030] USD 436.71 million
CAGR (%) 6.47%
Acetazolamide Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Acetazolamide Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Acetazolamide Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Acetazolamide Market, highlighting leading vendors and their innovative profiles. These include Aquatic Group, Avanscure Lifesciences Pvt Ltd., CTX Lifesciences Pvt Ltd, Emcure Pharmaceuticals Limited, Heritage Pharmaceuticals Inc, Lannett Co Inc., Lannett Company, Inc., LGM Pharma, LLC, Manus Aktteva Biopharma LLP, Mylan N.V., Nakoda Chemicals Ltd., Ningbo Hi-tech Biochemicals Co Ltd, Nostrum Laboratories Inc., Novast Laboratories Ltd., Polpharma SA, Shandong Octagon Chemicals Limited, Strides Pharma Science Limited, Strides Shasun Limited, Sun Pharmaceutical Industries, Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd, X-Gen Pharmaceuticals, Inc., and Zydus Pharmaceuticals (USA) Inc..

Market Segmentation & Coverage

This research report categorizes the Acetazolamide Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Dosage Form
    • Capsules
    • Injection
    • Tablets
  • Disease
    • Altitude Sickness
    • Epilepsy
    • Glaucoma
    • Heart Failure
    • Idiopathic Intracranial Hypertension
    • Periodic Paralysis
  • Distribution Channel
    • Hospital
    • Online Drug Store
    • Retail Drug Store
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Acetazolamide Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Acetazolamide Market?

3. What are the technology trends and regulatory frameworks in the Acetazolamide Market?

4. What is the market share of the leading vendors in the Acetazolamide Market?

5. Which modes and strategic moves are suitable for entering the Acetazolamide Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Acetazolamide Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of glaucoma and pertinent risk factors such as high blood pressure among the population
      • 5.1.1.2. Growing government and pharmaceutical organizations initiatives to increase awareness on glaucoma
      • 5.1.1.3. Application of acetazolamide in several treatment modalities
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns related to certain glitches during production process
      • 5.1.2.2. Augmenting availability of acetazolamide as generic medicine
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising innovation in the production of varied types of acetazolamide
      • 5.1.3.2. Augmenting availability of acetazolamide as generic medicine
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of considerable alternatives to acetazolamide in the market
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Acetazolamide Market, by Dosage Form

  • 6.1. Introduction
  • 6.2. Capsules
  • 6.3. Injection
  • 6.4. Tablets

7. Acetazolamide Market, by Disease

  • 7.1. Introduction
  • 7.2. Altitude Sickness
  • 7.3. Epilepsy
  • 7.4. Glaucoma
  • 7.5. Heart Failure
  • 7.6. Idiopathic Intracranial Hypertension
  • 7.7. Periodic Paralysis

8. Acetazolamide Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Online Drug Store
  • 8.4. Retail Drug Store

9. Americas Acetazolamide Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Acetazolamide Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Acetazolamide Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Aquatic Group
    • 13.1.2. Avanscure Lifesciences Pvt Ltd.
    • 13.1.3. CTX Lifesciences Pvt Ltd
    • 13.1.4. Emcure Pharmaceuticals Limited
    • 13.1.5. Heritage Pharmaceuticals Inc
    • 13.1.6. Lannett Co Inc.
    • 13.1.7. Lannett Company, Inc.
    • 13.1.8. LGM Pharma, LLC
    • 13.1.9. Manus Aktteva Biopharma LLP
    • 13.1.10. Mylan N.V.
    • 13.1.11. Nakoda Chemicals Ltd.
    • 13.1.12. Ningbo Hi-tech Biochemicals Co Ltd
    • 13.1.13. Nostrum Laboratories Inc.
    • 13.1.14. Novast Laboratories Ltd.
    • 13.1.15. Polpharma SA
    • 13.1.16. Shandong Octagon Chemicals Limited
    • 13.1.17. Strides Pharma Science Limited
    • 13.1.18. Strides Shasun Limited
    • 13.1.19. Sun Pharmaceutical Industries
    • 13.1.20. Taro Pharmaceutical Industries Ltd.
    • 13.1.21. Teva Pharmaceutical Industries Ltd
    • 13.1.22. X-Gen Pharmaceuticals, Inc.
    • 13.1.23. Zydus Pharmaceuticals (USA) Inc.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing